Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Incyte (INCY)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND – Research Report) and Incyte (INCY – Research Report) with bullish sentiments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ascendis Pharma (ASND)
In a report released today, Kelly Shi from Jefferies maintained a Buy rating on Ascendis Pharma, with a price target of $235.00. The company’s shares closed last Monday at $164.16, close to its 52-week high of $169.37.
According to TipRanks.com, Shi is a 3-star analyst with an average return of
Ascendis Pharma has an analyst consensus of Strong Buy, with a price target consensus of $230.15, representing a 35.0% upside. In a report issued on July 14, Citi also maintained a Buy rating on the stock with a $243.00 price target.
See the top stocks recommended by analysts >>
Incyte (INCY)
In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Incyte, with a price target of $86.00. The company’s shares closed last Monday at $70.16.
According to TipRanks.com, Frahm is a 4-star analyst with an average return of
Currently, the analyst consensus on Incyte is a Moderate Buy with an average price target of $79.75, representing a 13.4% upside. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $82.00 price target.
Read More on ASND:
Disclaimer & DisclosureReport an Issue
- Bullish Outlook on Ascendis Pharma: FDA Approval and Anticipated Product Launches Drive Buy Rating
- Buy Rating for Ascendis Pharma Driven by Skytrofa’s FDA Approval and Market Potential
- Ascendis Pharma Gains FDA Approval for Adult Growth Hormone Therapy
- Ascendis Pharma announces FDA approved SKYTROFA
- Ascendis Pharma’s Strong Market Performance and Potential Drive Buy Recommendation
